Sugi Predict

Sugi Predict / Compounds / SCHEMBL321575

SCHEMBL321575

SCHEMBL321575

COC(=O)c1cccc(OCC(=O)O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.66
▸ PKM P14618 1/20 0.63
▸ HTT P42858 1/20 0.63
▸ RAB9A P51151 3/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ POLB P06746 2/20 0.59
▸ BLM P54132 1/20 0.59
▸ MAPK1 P28482 1/20 0.58
▸ MAPT P10636 2/20 0.55
▸ MRGPRX4 Q96LA9 1/20 0.55
▸ ALOX15 P16050 1/20 0.55
▸ CYSLTR1 Q9Y271 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ LOXL2 Q9Y4K0 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2832791 0.87 SMN1; SMN2 (0.59) PKMHTTRAB9ASMN1; SMN2NPC1
SCHEMBL15103371 0.86 SMN1; SMN2 (0.58) LMNAPKMHTTRAB9ASMN1; SMN2
SCHEMBL6814984 0.86 SMN1; SMN2 (0.58) LMNAPKMHTTRAB9ASMN1; SMN2
SCHEMBL31286940 0.86 RAB9A (0.55) LMNAPKMHTTRAB9ASMN1; SMN2
SCHEMBL4496546 0.84 LMNA (0.58) LMNAPKMHTTPOLBMAPK1
SCHEMBL4234393 0.84 SMN1; SMN2 (0.57) LMNAPKMHTTRAB9ASMN1; SMN2
SCHEMBL320846 0.84 ALDH1A1 (0.59) RAB9ASMN1; SMN2NPC1POLBBLM
SCHEMBL4060556 0.83 MAOB (0.67) LMNAPKMHTTSMN1; SMN2MAPK1
SCHEMBL29953637 0.83 MAOB (0.67) LMNAPKMHTTSMN1; SMN2MAPK1
SCHEMBL31442462 0.83 SMN1; SMN2 (0.58) LMNAHTTRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113387938-B Substituted pyrimidine compound, preparation method, intermediate and application thereof 上海科技大学 2023-08-18 — — CN disclosed
CN-108472381-B Compounds and therapeutic uses thereof 森陶里治疗有限公司 2023-06-06 — — CN disclosed
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB/GB) (GB) 2021-12-02 — — US disclosed
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB/GB) (GB) 2021-12-02 — — US disclosed
US-10953100-B2 Compounds and therapeutic uses thereof CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2021-03-23 — — US disclosed
US-10953100-B2 Compounds and therapeutic uses thereof CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2021-03-23 — — US disclosed
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2018-10-04 — — US disclosed
WO-2017060729-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTAURI THERAPEUTICS LIMITED (GB) 2017-04-13 — — WO disclosed
WO-2017060729-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTAURI THERAPEUTICS LIMITED (GB) 2017-04-13 — — WO disclosed
EP-2404918-B1 PYRIDINE DERIVATIVE AS PPARY INHIBITOR DAIICHI SANKYO CO LTD (JP) 2016-11-30 — — EP disclosed
US-7238685-B2 Benzo-fused heterocycles as endothelin antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2007-07-03 — — US disclosed
US-20070054924-A1 Novel piperidines as chemokine modulators (ccr) ASTRAZENECA AB (SE) 2007-03-08 — — US disclosed
EP-1713772-A1 NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) AstraZeneca AB (SE) 2006-10-25 — — EP disclosed
WO-2005073192-A1 NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) ASTRAZENECA AB (SE) 2005-08-11 — — WO disclosed
US-20050124605-A1 Novel benzo-fused heterocycles as endothelin antagonisits ACTELION PHARMACEUTICALS LTD. 2005-06-09 — — US disclosed
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 — — US disclosed
WO-2003013545-A1 NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS ACTELION PHARMACEUTICALS LTD (CH) 2003-02-20 — — WO disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 — — US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 — — EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124605-A1 Novel benzo-fused heterocycles as endothelin antagonisits EDNRA, EDNRB, ECE1 LMNA 983/4885PKM 2621/4885HTT 523/4885
US-20070054924-A1 Novel piperidines as chemokine modulators (ccr) CCR3, CCR1, CCR4 LMNA 4676/4885PKM 2923/4885HTT 4877/4885
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 LMNA 3909/4885PKM 2743/4885HTT 2156/4885
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB LMNA 1535/4885PKM 2588/4885HTT 3050/4885
US-10953100-B2 Compounds and therapeutic uses thereof CD47, MYD88, NFATC1 LMNA 3909/4885PKM 2743/4885HTT 2156/4885
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 LMNA 3909/4885PKM 2743/4885HTT 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.